ACELYRIN, Inc. Announces Positive 16-Week Data From Its Global Phase 2B/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at Eular 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.